Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0EEDEE)
| ADC Name |
DXC-008
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
DXC-008; DXC008
Click to Show/Hide
|
|||||
| Organization |
Hangzhou DAC Biotechnology (DAC Biotech) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-PSMA/STEAP1 dual-target antibody
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1); Metalloreductase STEAP1 (STEAP1)
|
Antigen Info | ||||
| Payload Name |
Tubulysin B analog
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Sarcoma |
1 Trials
|
|||||
| Prostate cancer |
1 Trials
|